UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2021

 

 

Commission File Number: 001-39633

 

 

Abcam plc

(Translation of registrant’s name into English)

 

 

Discovery Drive

Cambridge Biomedical Campus

Cambridge, CB2 0AX

United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 27, 2021 Abcam plc (the “Company”) issued a regulatory news service announcement (the “Announcement”) announcing the completion of its acquisition of BioVision Inc. from Boai NKY Medical Holdings Ltd. (“NKY”) for total consideration of $340m. The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.

EXHIBIT INDEX

 

Exhibit
No.

  

Description

99.1    Regulatory News Service Announcement dated October 27, 2021


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ABCAM PLC
Date: October 27, 2021     By:  

/s/ Alan Hirzel

      Name:   Alan Hirzel
      Title:   Chief Executive Officer

 

 

Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Abcam Charts.
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Abcam Charts.